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Abstract
Objectives—To assess the effect of initiating antidepressant therapy with a generic prescription
on adherence to antidepressant therapy among Medicare patients. A second objective is to assess
how the effect might be moderated by the Medicare Part D coverage gap.
Research Design—Adherence to antidepressant therapy was measured by (a lack of) disruption
in medication use defined by a gap of >=30 days in antidepressant possession and monthly days of
possession, both measured over 180 days since antidepressant initiation. We used a 5% random
sample of Medicare fee-for-service beneficiaries who received a new depression diagnosis in the
first half of 2007 and initiated antidepressant therapy within 60 days (n=16,778). We estimated a
Cox proportional hazard model for antidepressant disruption and a mixed-effects linear model for
monthly possession. All analyses were stratified by four cohorts defined by Part D low-income
subsidy (LIS) status and Medicare entitlement (aged vs. disabled).
Results—Generic initiation was associated with improved adherence among all four cohorts,
with a stronger effect among the non-LIS patients. Hazard ratios for antidepressant disruption
ranged from 0.71 (95% CI: 0.53 to 0.96) among the non-LIS, disabled to 0.88 (95% CI: [0.79,
0.98]) among the LIS, aged. Generic initiation was associated with increases in days of monthly
possession in all four cohorts and an additional benefit during the coverage gap for non-LIS
patients.
Conclusions—Generic initiation can be an important tool to improve adherence to
antidepressant treatment among Medicare patients and to mitigate the negative effects of the Part
D coverage gap.
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Antidepressants are among the most prescribed drugs for U.S. adults.1 Among people 65
years or older, 14 percent use antidepressants annually for depression, anxiety, or another
indication.2 While adherence to antidepressants is critical to realizing the effectiveness of
antidepressant treatment,3, 4 around 40% of Medicare managed care patients discontinue
their antidepressant treatment prematurely. 5 High out-of-pocket costs due to lack of drug
coverage or high cost-sharing has been shown to decrease drug adherence in most
populations,6 including Medicare beneficiaries using antidepressant medication.7
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Generic antidepressants are now widely available.8 By 2007, most major brands of second-
generation antidepressants had generic equivalents in the U.S. market. Generic use has the
potential to improve adherence to antidepressant therapy because patient out-of-pocket costs
for generics are nearly always much lower than for brands.9 For example, for patients
receiving Medicare prescription benefits in 2011, the median co-payment was $7 for
generics, $42 for preferred brands, and $78 for non-preferred brands.10 Choice of generic or
brand name is partly a function of provider preferences.11 When a branded drug is
prescribed and in absence of a “Dispense as Written” request by the prescriber or the patient,
patients often receive a generic equivalent because of state mandates of generic
substitution12 or pharmacist discretion. The generic (vs. branded) status of the first
prescription is likely highly influential in determining generic or branded drug use
throughout the course of treatment and therefore may have important implications for
patient adherence to chronic medication therapy.
The cost advantage of generics has greater implications under Medicare’s current
prescription drug benefit (Part D) than under a traditional insurance plan because of the Part
D coverage gap. For example, in 2007 (the study year), under most plans, patients whose
total Part D-covered drug spending reached $2510.00 were responsible for 100% of drug
costs until their total spending reached $5726.00, or until the start of 2008. An estimated 3.4
million beneficiaries (about 14% of all Part D enrollees) reached the coverage gap in
2007.13 While the Affordable Care Act will take steps to gradually close the coverage gap
over the 10 years starting 2011, in the near term, differences in out-of-pocket costs between
branded and generic antidepressants will remain greater during the coverage gap than
otherwise.
In this study, we assessed the effects of initiating antidepressant treatment with a generic
(vs. branded) prescription (“generic initiation”) on adherence to antidepressant therapy for
the treatment of depression. Our study contributes to the literature by examining both the
effect of generic initiation by itself and how the effect might be moderated by the presence
of the Medicare Part D coverage gap.
Methods
Data
We used data from a 5% random sample of beneficiaries with depression in 2006–2007
from the Medicare Chronic Condition Data Warehouse (CCW).14 Files used in this study
included carrier claims and the Part D Prescription Drug Event file. We also used the
Beneficiary Summary File and Chronic Condition Summary File to derive demographic and
comorbidity information for beneficiaries.
Study Sample
Our study population is Medicare fee-for-service patients who experienced a new episode of
depression and subsequently initiated antidepressant therapy within 60 days of the new
depression diagnosis. This is a population with a clear clinical indication for depression
treatment. To be included in the analysis, all beneficiaries were required to be continuously
enrolled in Medicare Parts A and B throughout 2006 and 2007. Because Part D had an
enrollment deadline of May 11 in 2006, we further required beneficiaries to be continuously
enrolled in Part D from July 1, 2006 to December 31, 2007.
To identify patients experiencing a new episode of depression, we first identified, for each
patient, the first physician service claim between January 1 and June 30 of 2007 that had
major depression, depressive disorder not elsewhere classified, or dysthymia as a primary or
secondary diagnosis (ICD-9 codes: 296.2x, 296.3x, 311x, and 300.4x) (the “index
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diagnosis”). We further excluded patients who had any physician claim with a depression
diagnosis or antidepressant use during the 6 months prior to the index diagnosis. We then
restricted the sample to patients who filled an antidepressant prescription within 60 days of
the index date. The resulting study sample contained patients who initiated antidepressant
therapy no later than July 4 of 2007 to allow for follow-up data covering 180 days after
initiation for every patient. We excluded 111 patients who had missing Part D benefit phase
information. We also excluded a small number of beneficiaries who were entitled to
Medicare because of end-stage renal disease.
More than half of patients in the study sample received the Part D low income subsidy (LIS)
and thus were not subject to the coverage gap. Among patients not receiving LIS, we
excluded patients who were already in the coverage gap by the time they initiated
antidepressant therapy (n=434), since these patients faced very different cost-sharing
compared to patients who transitioned into the coverage gap after antidepressant initiation.
Among non-LIS patients who transitioned into the coverage gap during the 180 days, about
20% spent through the coverage gap later in 2007 and transitioned to the catastrophic
coverage phase in which they had almost complete coverage. A recent study of a depression
cohort found that patients who eventually attained catastrophic coverage did not change
their medication use while in the coverage gap.15 We thus excluded these patients (n=431)
in our main analysis. In a sensitivity analysis, we included both types of patients to examine
the robustness of our findings. Our main analytic sample included 16,778 beneficiaries.
We identified four distinct patient cohorts defined by their Medicare entitlement status (aged
vs. disabled) and Part D LIS status. Compared to the aged, disabled beneficiaries differ in
both socioeconomic status and complexity of health care needs. Patients receiving LIS are
either Medicare-Medicaid dual enrollees or have limited income or resources;16 as shown
below, they also have more co-morbid conditions. We thus chose not to treat the LIS
patients as a “control” cohort for the non-LIS patients (since their baseline trends in
medication may not be comparable), but instead stratified all our analysis by the four patient
populations.
We used the Multum Lexicon drug classification system17 to identify antidepressants (and
whether a given prescription was generic or branded) based on the National Drug Code. We
used drug dispensing date and days of supply to determine time intervals during which a
patient was in possession of antidepressants. When two or more intervals overlapped, we
counted the overlapping period only once.
Main Outcome Measures
We created two measures of antidepressant adherence. The first measure is disruption in
antidepressant therapy during the 180 days after initiation, equal to 1 if there was a gap in
antidepressant possession of 30 days or longer and 0 otherwise. Patients who switched
medication during the 180 days were considered adherent (i.e., no disruption) as long as they
did not experience a gap of >=30 days. A follow-up of 180 days was based on depression
treatment guidelines that recommend minimum length of pharmacotherapy during acute and
continuation phases of treatment.3, 4, 18 The 30-day gap was defined so that patients who
retained antidepressants from previous fills or who had a “wash-out” period between
medication changes would not be incorrectly classified as non-adherent.19
The second measure, monthly days of antidepressant possession, is defined as the number of
days in each of the six months following antidepressant initiation that the patient was in
possession of antidepressants. We chose a monthly measure of possession (rather than the
typical medication possession ratio over 180 days) because the monthly measure allows us
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to examine the dynamics of antidepressant use in relationship to the onset of the coverage
gap.
Independent Variables
Our primary independent variable is the generic/brand status of the first prescription. Of all
the branded initiations in our sample, 83% were one of three antidepressants that did not yet
have a generic equivalent on the U.S. market in 2007: Lexapro (generic name: escitalopram,
a selective serotonin reuptake inhibitor or SSRI; accounting for 44% of all branded
initiations), Cymbalta (duloxetine, a serotonin and norepinephrine reuptake inhibitor or
SNRI; 20%) and Effexor XR (venlafaxine XR, an SNRI; 19%). While our main analysis
included all classes of antidepressants, we conducted a sensitivity analysis by including only
patients who initiated their treatment with a generic or branded SSRI.
For non-LIS patients, whose Part D coverage includes a coverage gap, a second independent
variable of interest was an indicator of whether the patient was in the coverage gap at a
given time. In analyses of both outcomes, this indicator is time-varying since patients may
transition into the coverage gap during the follow-up.
Statistical Analysis
For disruption in antidepressant therapy, we estimated a Cox proportional hazard model of
time to disruption. For non-LIS patients, in addition to generic initiation, independent
variables included Part D benefit phase (coverage gap vs. pre-coverage gap) and an
interaction between generic initiation and coverage gap. This allowed us to examine if the
effect of generic initiation was stronger as patients experienced the coverage gap. We
conducted tests of the proportional hazard assumption based on Schoenfeld residuals.20
For monthly days with antidepressant possession, we estimated a mixed-effects linear model
using data at the patient-month level, with a patient-level random intercept to account for
correlations between multiple observations clustered within a given patient. Generic
initiation was the primary independent variable. The models estimated among the non-LIS
cohorts also included dichotomous indicators of number of complete months that a patient
had been in the coverage gap, which ranged from 1 to 5. This was to allow the effect of
coverage gap to differ with the length of time spent in the coverage gap. Interaction terms
between generic initiation and each of the coverage gap month indicators were also
included. To control for time patterns in antidepressant use that are independent from the
effects of generic initiation and experience of the coverage gap, we included ordinal
indicators of months following antidepressant initiation.
In all analyses, we controlled for patient demographics (age, gender, race/ethnicity),
measures of patient disease burden (indicators of 9 comorbid chronic condition categories
based on CCW definition21 and the natural log of total prescription drug spending in 2007),
and the specialty of the clinician associated with the index clinical encounter that established
the new depression diagnosis (primary care, mental health specialty, or other medical
specialty).
Results
Of the 16,778 patients in our study sample, 65% received LIS in 2007 compared with a
national average of 36%,16 reflecting the substantially lower socioeconomic status of
patients with depression (Table 1). Close to 50% of LIS patients were entitled to Medicare
because of disability rather than old age compared to 11% among the non-LIS sample. The
LIS sample was less likely to be white and had a greater number of co-morbid conditions.
Total prescription drug costs in 2007 for the two cohorts receiving LIS were 2–3 times
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higher than the non-LIS cohorts of the same entitlement status. Patients receiving LIS were
also more likely to have received their depression diagnosis from a mental health specialist,
and less likely to have received it from a primary care clinician. Of the non-LIS, 30% of the
aged transitioned into the coverage gap during the 180-day follow-up compared to 25% of
the disabled.
The rate of generic initiation ranged from 62% to 68% across the four patient cohorts. Of all
patients with generic initiation, 11.6% switched to a branded antidepressant within 180 days,
while 30.6% of patients with branded initiation switched to generics, indicating strong
persistence of generic (or branded) choice throughout treatment episode and significance of
the initial drug choice. Mean out-of-pocket cost for a 30-day supply of antidepressants was
substantially lower for generic vs. branded initiations: for the LIS, it was $1.00 if generic
compared to $3.71 if branded; for the non-LIS, it was $6.78 if generic compared to $35.78 if
branded.
Antidepressant Disruption
Rate of disruption in antidepressant therapy ranged from 29.3% (95% CI: 28.1–30.4%)
among the LIS, aged to 39.3% (95% CI: 35.6–43.1%) among the non-LIS, disabled (Table
1). Figures 1A and 1B show (unadjusted) Kaplan-Meier survival curves by patient disability
status and generic status of first antidepressant for LIS and non-LIS patients, respectively.
Both figures show a sharp increase in disruption (decline in the survival curves) at 30 days
after antidepressant initiation. Among the LIS (Figure 1A), a greater proportion of disabled
patients with generic initiation disrupted at 30 days; their survival curve was below those of
the other three groups for the rest of the follow-up. Among the non-LIS (Figure 1B),
survival curves for all four groups traced each other closely until around the 120th day when
disabled patients with branded initiation started to experience a greater risk of disruption.
Tests of the proportional hazard assumption indicated no evidence of violation of the
assumption in any of the Cox models we estimated. Results (Table 2) show that generic
initiation was associated with a lower hazard of treatment disruption across all four cohorts.
Among LIS patients, the Hazard Ratio (HR) for generic initiation was 0.88 (95% CI: 0.79–
0.98, p=0.020) for the aged and 0.84 (95% CI: 0.75–0.93, p=0.001) for the disabled. For the
non-LIS patients, HRs for generic initiation were lower: 0.78 (95% CI: 0.70–0.87, p<0.001)
among the aged and 0.71 (95% CI: 0.53–0.96, p=0.025) among the disabled. The HR
associated with the coverage gap was 2.05 (95% CI: 1.18–3.55, p=0.010) among the non-
LIS, disabled. The HRs for the interaction between generic initiation and the coverage gap
were below one in both analyses but not statistically significant.
Monthly Antidepressant Possession
As depicted in Figures 2A and 2B, all four cohorts experienced sharp declines in monthly
possession from the first to second month. The non-LIS, disabled patients with a branded
initiation began to experience a sharper decline in possession in the 4th month, leading to 2–
4 fewer days of possession in Month 6 compared with the other three cohorts (Figure 2B).
Based on the mixed-effects models (Table 3), generic initiation was associated with a small
but statistically significant increase in monthly possession in all four cohorts: 0.6 days (95%
CI: 0.2–1.0, p=0.003) for the LIS, aged and 0.7 days (95% CI: 0.3–1.1, p<0.001) for the
LIS, disabled; 0.9 days (95% CI: 0.5–1.4, p<0.001) for the non-LIS, aged and 2.1 days (95%
CI: 0.7–3.4, p<0.001) for the non-LIS, disabled. For the non-LIS, aged, experiencing the
coverage gap was not significantly associated with reductions in monthly possession except
for the 3rd month in the coverage gap (1.1 fewer days, 95% CI: −2.2–0.0, p=0.045). For the
disabled, however, the coverage gap had a significant effect while patients were
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experiencing the 2nd (−4.1 days, 95% CI: −6.6 to −1.7, p=0.001) and 3rd complete month
(−4.1 days, 95% CI: −7.2 to −1.0, p=0.001) in the coverage gap. Generic initiation was
associated with an additional increase in monthly possession among non-LIS patients
experiencing the coverage gap. For example, for disabled patients, generic initiation was
associated with an additional 4.1 days (95% CI: 0.4 to 7.8, p=0.032) of possession when
patients were experiencing the 2nd month in the coverage gap.
Sensitivity analyses that included non-LIS patients who were experiencing the coverage gap
at antidepressant initiation and those who later transitioned into catastrophic coverage
yielded consistent results regarding the effect of generic initiation for both outcomes,
although effects of the coverage gap on adherence were slightly weaker in this larger
sample. Sensitivity analysis that was limited to SSRI initiations only estimated comparable
effect sizes for generic initiation with larger confidence intervals.
Discussion
Across four cohorts of fee-for-service Medicare beneficiaries newly diagnosed with
depression and treated with antidepressants in 2007, we found that initiating the therapy
with a generic antidepressant was consistently associated with increased medication
adherence. This effect was stronger among the two non-LIS cohorts and strongest among the
non-LIS, disabled. The beneficial effect of generic initiation was augmented for the outcome
of monthly antidepressant possession while non-LIS patients were experiencing the Part D
coverage gap.
Previous studies have linked out-of-pocket cost differentials between generic and branded
medications to substantially increased adherence among patients starting with a generic
medication for several chronic medical conditions.9 Our results suggest that beneficial
effects of generic use apply to antidepressant therapy as well. However, such benefits may
vary across patient populations. For example, a recent study of commercially insured
patients did not find generic initiation to be associated with a greater likelihood of refill of
the initially prescribed antidepressant.22 The consistent benefits of generic initiation found
in our study, regardless of LIS status, may reflect the lower socioeconomic status of
depressed Medicare beneficiaries and their greater sensitivity to cost differentials between
generic and branded drugs. Our findings thus lend strong support for generic initiation as a
means to improve antidepressant adherence among Medicare patients.
Our findings also suggest that, while the Part D coverage gap may be detrimental to
antidepressant adherence, the benefits of generic initiation may mitigate the negative effects.
Disabled patients not receiving LIS may be especially vulnerable to increased out-of-pocket
cost during the coverage gap, and appear to benefit most from the protective effect of
generic initiation.
About half of the disruption in antidepressant therapy across all patient cohorts occurred at
30 days after initiation, which, for most patients, also marked the end of the first
prescription. Myriad factors may underlie the dramatic decline in adherence by the end of
the first month. Beneficiaries may discontinue medication due to lack of response, side-
effects, and a lack of continued medication management (dose titration, medication switch
or augmentation). Physicians may not have adequately educated patients on antidepressant
treatment when prescribing the medication and/or may not have followed up with sufficient
intensity. Medication management accompanied by systematic clinical assessment may be
important to further improve adherence 23.
In our unadjusted analysis of the LIS cohorts, disabled patients with generic initiation were
shown to have worse adherence compared to disabled patients with branded initiation, which
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was inconsistent with findings of the adjusted analysis. Disabled patients receiving LIS were
particularly vulnerable to socioeconomic disadvantages that were positively associated with
generic initiation but, at the same time, negatively associated with adherence. In an
unadjusted analysis, confounding by these factors may have outweighed the effect of generic
initiation.
One limitation of our study is that we are unable to measure all of the clinical characteristics
of patients that may influence choice of brand vs. generic antidepressant. For example,
clinicians may have selectively prescribed branded antidepressants to patients who they
perceived as having a greater risk of non-adherence if started on older, generic drugs.
However, we do not believe this is likely to bias our estimates for several reasons. First,
recent evidence shows very similar efficacy and side-effect profiles among second-
generation antidepressants (including the branded drugs seen in this study).24 For a given
patient who is “treatment naïve”, clinicians have little ground to predict if one antidepressant
would be more effective or tolerable than another, especially among the second-generation
classes.25 Thus, clinician choice of branded vs. generic initiation based on clinical
characteristics may be quite limited. Second, previous studies have consistently shown that
provider preferences are a much stronger determinant of medication choice than are patient
clinical needs; generic initiation status may largely reflect prescriber and patient familiarity
with the drug chosen and affordability to the patient.26–28
Other limitations include the following. Our data are for Medicare fee-for-service patients
only; our findings may not extend to Medicare managed care patients. Like all studies that
use claims data for adherence research, we based inferences on antidepressant possession,
not drugs taken. As a result, the sharp decline in adherence seen at the end of the first month
reflects failures to renew 30-day prescriptions and should not be interpreted as non-
adherence at exactly 30 days after initiation. Our measures of antidepressant adherence
reflected one dimension of guideline-concordant care, namely, continuation of therapy for
an extended period of time. We did not have information on adequacy of dosage. We did not
examine medication switches or augmentations, two recommended strategies when patients
fail to respond to initial treatment or have serious side effects 3, 4, 29 because we were not
able to determine the clinical validity of either. The clinical significance of missing a few
days of antidepressant medication on a monthly basis is less clear than having a significant
gap in treatment since some antidepressants have long half-lives. Thus, findings regarding
monthly possession should be interpreted as secondary to those pertaining to disruption. We
focused on generic (vs. branded) initiation and did not consider subsequent switches
between generic and branded antidepressants, which were infrequent. We also do not have
information on prescribers or the benefit design of the Part D prescription drug plans.
Conclusions
Our study provides strong evidence supporting generic initiation to improve adherence to
antidepressant therapy among Medicare patients. The benefits result from the lower out-of-
pocket cost associated with generic antidepressants. These benefits were augmented while
patients were experiencing the coverage gap under Part D. Our findings imply that generic
prescribing, a strategy within easy reach of clinicians, can be an important tool to further
improve adherence to antidepressant treatment and to mitigate negative effects of the Part D
benefit structure. More broadly, to assist their patients in making health care more
affordable, clinicians should consider the economic impact of their treatment decisions and
raise the issues of ability-to-pay with patients and discuss options. States that do not
currently mandate generic substitution (unless with a DAW request by the prescriber or
patient) or that require patient consent for generic substitution may consider more restrictive
policies to further reap the benefits of generic use.
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Encouraging prescribers to initiate antidepressant treatment with a generic drug has the
potential to improve antidepressant adherence among Medicare patients.
• Starting patients with generics had benefits for antidepressant adherence by
lowering out-of-pocket costs for all patients and by mitigating the effect of the
Part D coverage gap faced by patients not receiving low-income subsidies.
• Managed care organizations may target prescriber drug choice behaviors to
further improve antidepressant adherence and effectiveness of antidepressant
treatment among its members.
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Survival curves for disruption in antidepressant therapy by disability status and generic
status of first antidepressant.
LIS – Low Income Subsidy
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Monthly days of antidepressant possession, by disability status and generic status of first
antidepressant
LIS – Low Income Subsidy
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Aged (n=5,679) Disabled (n=5,210) Aged (n=5,243) Disabled (n=646)
Age – y (± S.D.) 78.9 (±8.3) 49.0 (±9.9) 77.9 (±7.6) 53.6 (8.5)
Female sex – no. (%) 4716 (83.0) 3393 (65.1) 4250 (81.1) 400 (61.9)
Race/ethnicity – no. (%)
 White, non-Hispanic 4668 (82.4) 4195 (80.7) 5080 (97.0) 569 (88.1)
 Black, non-Hispanic 560 (9.9) 679 (13.1) 83 (1.6) 45 (7.0)
 Hispanic 272 (4.8) 177 (3.4) 32 (0.6) 10 (1.6)
 Other race/ethnicity 166 (2.9) 147 (2.8) 43 (0.8) 22 (3.4)
# of co-morbid conditions† (± S.D.) 2.9 (±1.5) 1.3 (±1.3) 2.1 (±1.4) 1.0 (±1.2)
Total Rx costs in 2007 – $ (± S.D.) 5330.3 (±4095.8) 7101.3 (±7476.2) 2674.8 (±2591.9) 2716.0 (±4221.0)
Diagnosing clinician – no. (%)
 Primary care 3732 (65.7) 2894 (55.6) 3930 (75.0) 387 (59.9)
 Mental health specialty 1457 (25.7) 1506 (28.9) 819 (15.6) 179 (27.7)
 Other specialty 490 (8.6) 810 (15.6) 494 (9.4) 80 (12.4)
Generic (vs. branded) initiation# – no. (%) 3862 (68.0) 3225 (61.9) 3581 (68.3) 425 (65.8)
Experienced coverage gap during 180 days – no. (%) - - 1567 (29.9) 164 (25.4)
Disruption in antidepressant therapy over 180 days‡ –
% (95% CI)
29.3 [28.1, 30.4] 31.4 [30.2, 32.7] 35.2 [33.8, 36.5] 39.3 [35.6, 43.1]
Monthly possession of antidepressants – days (95% CI)
 1st month 29.7 [29.6, 29.7] 29.7 [29.7, 29.8] 29.7 [29.7, 29.8] 29.8 [29.7, 29.9]
 2nd month 23.9 [23.6, 24.2] 22.7 [22.4, 23.0] 22.5 [22.2, 22.8] 21.5 [20.6, 22.4]
 3rd month 23.5 [23.3, 23.8] 23.0 [22.7, 23.3] 22.6 [22.3, 22.9] 22.0 [21.1, 22.9]
 4th month 22.8 [22.6, 23.1] 22.4 [22.0, 22.7] 21.3 [21.0, 21.7] 20.1 [19.2, 21.0]
 5th month 22.7 [22.5, 23.0] 22.2 [21.9, 22.5] 21.2 [20.9, 21.5] 20.0 [19.0, 20.9]
 6th month 22.6 [22.3, 22.9] 21.8 [21.5, 22.1] 20.8 [20.5, 21.2] 19.0 [18.1, 20.0]
LIS – Low Income Subsidy; S.D. – standard deviation; CI - confidence interval
†
# of co-morbid conditions is a count of the presence of the following conditions: Alzheimer’s disease or dementia, cardiovascular or
cerebrovascular conditions (atrial fibrillation, heart failure, ischemic heart disease, stroke/transient ischemic attack), chronic kidney disease,
chronic obstructive pulmonary disease, diabetes, eye conditions (cataract or glaucoma), hip fracture, osteoporosis/rheumatoid arthritis/
osteoarthritis, and cancer (breast, colorectal, prostate, lung, endometrial cancer). All conditions were defined based on Chronic Condition
Warehouse rules based on ICD-9 diagnostic codes in Medicare claims.
#
Generic initiation is 1 (0 otherwise) if the prescription filled at the initiation of the therapy was a generic (vs. branded) antidepressant.
‡
Disruption in antidepressant therapy was defined as a gap of 30 days or longer in the possession of antidepressants.
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Table 2
Disruption in antidepressant therapy
Hazard Ratio [95% CI] (p-value)
LIS Non-LIS
Aged Disabled Aged Disabled




0.78 [0.70, 0.87] (p<0.001) 0.71 [0.53, 0.96] (p=0.025)
Coverage gap (vs. pre-
coverage gap)
1.27 [0.98, 1.65] (p=0.075) 2.05 [1.18, 3.55] (p=0.010)
Generic initiation * coverage
gap
0.92 [0.65, 1.30] (p=0.621) 0.70 [0.27, 0.79] (p=0.455)
LIS – Low Income Subsidy; S.D. – standard deviation; CI - confidence interval
Results are based on Cox proportional hazard models that controlled for patient demographics (age, gender, race/ethnicity), measures of patient
disease burden (indicators of 9 co-morbid conditions based on Chronic Condition Warehouse definition and the natural log of total prescription
drug spending in 2007), and the specialty of the diagnosing clinician associated with the index outpatient visit (primary care, mental health
specialty, or other medical specialty).
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Table 3
Monthly days of antidepressant possession
Incremental Days [95% CI] (p-value)
LIS Non-LIS
Aged Disabled Aged Disabled




0.9 [0.5, 1.4] (p<0.001) 2.1 [0.7, 3.4] (p=0.002)
1st month in coverage gap 0.1 [−0.7, 0.8] (p=0.885) −0.6 [−2.7, 1.5] (p=0.584)
2nd month in coverage gap 0.1 [−0.8, 0.9] (p=0.896) −4.1 [−6.6, −1.7] (p=0.001)
3rd month in coverage gap −1.1 [−2.2, 0.0] (p=0.045) −4.1 [−7.2, −1.0] (p=0.009)
4th month in coverage gap −1.2 [−2.8, 0.3] (p=0.116) −3.8 [−7.7, 0.2] (p=0.062)
5th month in coverage gap −0.4 [−2.8, 2.0] (p=0.749) 0.7 [−4.6, 6.0] (p=0.792)
Generic initiation * 1st month in coverage
gap
1.0 [0.0, 2.0] (p=0.047) −1.9 [−5.0, 1.2] (p=0.224)
Generic initiation * 2nd month in coverage
gap
0.8 [−0.4, 1.9] (p=0.177) 4.1 [0.4, 7.8] (p=0.032)
Generic initiation * 3rd month in coverage
gap
1.4 [0.0, 2.8] (p=0.047) 4.4 [−0.2, 9.1] (p=0.063)
Generic initiation * 4th month in coverage
gap
2.4 [0.4, 4.3] (p=0.017) 2.9 [−3.0, 8.9] (p=0.333)
Generic initiation * 5th month in coverage
gap
0.3 [−2.9, 3.6] (p=0.847) 1.8 [−6.5, 10.1] (p=0.676)
LIS – Low Income Subsidy; S.D. – standard deviation; CI - confidence interval
Results are based on mixed-effects linear models at the patient-month level, with a patient-level random intercept. All models controlled for patient
demographics (age, gender, race/ethnicity), measures of patient disease burden (indicators of 9 co-morbid conditions based on Chronic Condition
Warehouse definition and the natural log of total prescription drug spending in 2007), and the specialty of the diagnosing clinician associated with
the index outpatient visit (primary care, mental health specialty, or other medical specialty).
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